Skip to the story

Vol. I · No. 1

Morning ColumnThe letter

Current News · Sourced report

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities

News Desk · Nov 17, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Nov 17, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world.

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide. Nov 17, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.